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ABSTRACT
Humans and other mammals are colonized by microbial agents across the 
kingdom which can represent a unique microbiome pattern. Dysbiosis of the 
microbiome has been associated with pathology including cancer. We have identified a 
microbiome signature unique to ovarian cancers, one of the most lethal malignancies 
of the female reproductive system, primarily because of its asymptomatic nature 
during the early stages in development. We screened ovarian cancer samples along 
with matched, and non-matched control samples using our pan-pathogen array 
(PathoChip), combined with capture-next generation sequencing. The results show 
a distinct group of viral, bacterial, fungal and parasitic signatures of high significance 
in ovarian cases. Further analysis shows specific viral integration sites within the 
host genome of tumor samples, which may contribute to the carcinogenic process. 
The ovarian cancer microbiome signature provides insights for the development of 
targeted therapeutics against ovarian cancers.
INTRODUCTION
In the US, ovarian cancer is the second most 
common and most deadly of the gynecologic cancers, 
affecting 1 in 70 women, with a mortality rate of 1% of 
all women (http://www.merckmanuals.com/professional/
gynecology-and-obstetrics/gynecologic-tumors/ovarian-
cancer). This accounts for its being the 5th leading cause 
of cancer-related deaths in women, causing an estimated 
22,280 new cases (1.3% of all new cancer cases) and 
14,240 deaths (2.4% of all cancer deaths) in 2016 (www.
cancer.org). Importantly, the incidence is even higher in 
developed countries (http://www.wcrf.org). Due to the 
asymptomatic nature of the early stage of the disease 
most patients go undiagnosed until the cancer reaches an 
advanced stage [1]. Thus finding specific biomarkers for 
early diagnosis of the disease is of utmost importance. 
Many studies have found that DNA of the Human 
Papillomavirus (HPV)-16 and HPV-18 is associated with 
ovarian carcinomas [2–5]. However, recent studies from 
our laboratory and others [6–8] have found that the tumor 
microbiome may be far more complex. We have defined 
unique microbial signatures associated with triple negative 
breast cancer and head and neck cancer [6] (Banerjee 
et al., unpublished). These signatures potentially provide 
insight into predisposition, presence or prognosis of the 
cancer. Such diagnostic data may increase the therapeutic 
potential for early detection and treatment. 
In the present study we used the PathoChip, 
a microarray-based approach comprised of probes 
for detection of all known viruses and other human 
pathogenic microorganisms [6, 9]. The current version 
of the PathoChip contains 60,000 probes representing all 
known viruses, 250 helminths, 130 protozoa, 360 fungi 
and 320 bacteria [6, 9]. In addition to probes that identify 
specific viruses and micro-organisms, PathoChip also 
contains family-specific conserved probes which provide 
a means for detecting previously uncharacterized members 
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of a family. Using this technique we have previously 
identified a microbiome signature associated with triple 
negative breast cancers [6], and oropharyngeal squamous 
cell carcinomas (Banerjee et al., unpublished).
We have used 99 ovarian cancer samples and 
20 matched (tissue adjacent to the tumor deemed non-
cancerous by pathological analysis) and 20 unmatched 
control samples to define a specific ovarian cancer 
microbiome signature which is distinct from the signature 
of the controls. To corroborate these results we selected 
microbial probes across the different organisms detected 
by the PathoChip screen and used them to capture 
the signatures from the ovarian cancer samples. This 
enrichment allowed targeted next generation sequencing 
to validate the PathoChip screen results and also allowed 
us to identify microbial insertion sites in the host genome 
of the ovarian cancer tissues. The data generated in this 
study suggest a robust and specific microbiome associated 
with ovarian cancer. Whether or not these organisms 
contribute as direct drivers to the cancer or simply 
persist as bystanders or secondary in a supportive tumor 
microenvironment remains to be determined. 
RESULTS
Microbial signatures uniquely associated with 
ovarian cancer
We used the PathoChip technology to screen ovarian 
cancer samples, as well as matched and non-matched 
controls. To establish the microbiome signatures we 
compared the average hybridization signal for each probe 
in the cancer samples versus the controls. Those probes 
that detected significant hybridization signals in the cancer 
samples (p-value < 0.05, log fold change in hybridization 
signal > log1), were considered. Additionally, we 
calculated the percent prevalence of the specific microbial 
signatures in the cancer samples, these data indicate how 
prevalent a significant virus or microorganism signature 
is in the cancer samples regardless of the hybridization 
intensity. Similarly, we also detected microbiome 
signatures in the matched and non-matched control 
samples versus the ovarian cancer samples. The signature 
of non-matched controls is quite distinct while there is 
more similarity between the tumor tissue and the matched 
controls. However, there are distinct viral and microbial 
signatures in the tumor-specific signature.
Viral signatures associated with ovarian cancer
The viral signatures detected in the ovarian 
cancer and control samples are shown according to 
their decreasing hybridization signal along with their 
prevalence in Figure 1A–1E. By summing all of the 
hybridization signals for viral families we found that 
the predominant signatures detected in the ovarian 
cancers were positive sense single stranded RNA 
viruses, double stranded DNA viruses and negative 
sense single stranded RNA viruses (Figure 1A). Among 
the signatures for viral families detected, 23% were 
identified as tumorigenic viruses (Figure 1B), and were 
prevalent on average, in more than 50% of the cancer 
samples screened (Figure 1C). Signatures of Retroviridae 
showed the highest hybridization signal, followed by 
that of Hepadnaviridae, Papillomaviridae, Flaviviridae, 
Polyomaviridae and Herpesviridae (Figure 1C). Notably, 
Papillomaviridae family members have previously been 
shown to be associated with ovarian cancer [2, 10]. 
Interestingly, we found papilloma virus signatures in 
the cancer samples and in the non-matched controls, 
but not at significant levels in the matched controls. 
The papilloma virus signatures in the ovarian cancer 
samples screened included not only HPV16 and 18 but 
also other HPVs (HPV-2, 4, 5, 6b, 7, 10, 32, 48, 49, 50, 
60, 54, 92, 96, 101, 128, 129, 131, 132) (Figure 1F). 
However the HPV signatures in matched controls that 
showed significantly high hybridization signal intensity 
over those in cancer samples, were HPV 41, 88, 53 and 
103 (Figure 1F). We also found an abundance of other 
viral signatures in the ovarian cancer samples (Table 1, 
Figure 1F, and Supplementary Figure 1), including 
Herpesviridae (HHV4, HHV8, HHV5, HHV6a, HHV 6b), 
Poxviridae (both pox and parapoxvirus), Polyomaviridae 
(Merkel cell polyomavirus, JC polyomavirus, Simian virus 
40), Retroviridae (Simian foamy virus, Mouse mammary 
tumor virus).
In the adjacent matched controls and in non-
matched control samples, we also detected signatures 
of tumorigenic viral families, along with other viral 
signatures (Figure 1D and 1E). Figure 1G and Table 1 
shows the common as well as unique viral signatures 
detected in ovarian cancer, when compared to the matched 
and non-matched controls.
The data suggest a substantial perturbation 
of the virome in ovarian cancer. First, the average 
hybridization signal for the viral families detected in 
the cancer is actually lower compared to the control 
samples (compare Supplementary Figure 1 with Figure 
1C–1E); Second, despite lower hybridization signal for 
many viruses in the cancer samples, the viral families 
present are quite different from controls; for example, 
signatures of Anelloviridae, Astroviridae, Birnaviridae, 
Bornaviridae, Caliciviridae, Hepadnaviridae, Iridoviridae, 
Paramyxoviridae, Rhabdoviridae and Togaviridae 
were detected at significant levels only in the cancer 
samples (Supplementary Figure 1, Table 1). Third, 
among the viral families detected in both cancer and 
control samples, specific members of a virus family 
differed between cancer and controls. For example, 
specific molecular signatures of the high risk HPV16 
and 18 were detected only in the cancer samples and 
not in the matched or non-matched control group. 
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Table 1. Microbial signatures detected in ovarian cancer and control samples
Cancer MC NC Cancer/MC Cancer/NC Cancer/MC/NC
Viral 
signatures
Anelloviridae
Astroviridae
Birnaviridae
Bornaviridae
Caliciviridae
Hepadnaviridae
Iridoviridae
Paramyxoviridae
Rhabdoviridae
Togaviridae
Nodaviridae 
Parvoviridae
Arenaviridae
Circoviridae
Flaviviridae
Orthomyxoviridae
Papillomaviridae
Adenoviridae
Bunyaviridae
Coronaviridae
Herpesviridae
Picornaviridae
Polyomaviridae
Poxviridae
Reoviridae
Retroviridae
Bacterial 
signatures
Proteobacteria:
Aeromonas 
Agrobacterium
Anaplasma
Arcobacter
Bartonella
Brucella
Burkholderia
Campylobacter
Coxiella
Francisella
Helicobacter
Klebsiella
Legionella
Methylobacterium
Neisseria
Orientia
Pasteurella
Proteus
Pseudomonas
Rickettsia
Shewanella
Shigella
Sphingomonas
Stenotrophomonas
Vibrio
Wolbachia
Yersinia
Firmicutes:
Abiotrophia
Bacillus
Enterococcus
Erysipelothrix
Geobacillus
Lactobacillus
Lactococcus
Listeria
Pediococcus
Peptoniphilus
Staphylococcus
Bacteroidetes:
Bacteroides
Flavobacterium
Porphyromonas
Prevotella
Actinobacteria:
Corynebacterium
Propionibacterium
Chlamydiae:
Chlamydia
Chlamydophila
Fusobacteria:
Fusobacterium
Streptobacillus
Spirochaetes:
Leptospira
Treponema
Tenericutes:
Mycoplasma
Ureaplasma
Proteobacteria:
Morganella
Proteobacteria:
Brevundimonas
Campylobacter
Proteobacteria:
Azorhizobium
Escherichia
Firmicutes:
Clostridium
Proteobacteria:
Bordetella
Salmonella
Bacteroidetes:
Chryseobacterium
Actinobacteria:
Mycobacterium
Firmicutes:
Streptococcus
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Instead the non-matched control samples showed 
significant detection of molecular signatures of the 
L1 major capsid gene of HPV 41, 88, 53, and E1 gene 
of HPV 103 (Figure 1F and Supplementary Table 2). 
A similar situation was detected with the poxviridae. 
While signatures of poxviridae that are conserved 
across the family were significantly detected in cancer 
as well as the controls (both matched and non-matched) 
(Figure 1F, Supplementary Table 2), highly specific 
signatures of certain poxviruses [Monkeypox virus, 
Myxoma virus, Yaba monkey tumor virus (YMTV), 
Yaba-like disease virus (YLDV)] and parapoxviruses 
[(Pseudocowpox virus (PCP), Orf virus (Orf), Bovine 
papular stomatitis virus (BPSV)] were detected only in 
the ovarian cancer samples (Figure 1F, Supplementary 
Table 2). The specific parapoxvirus signatures detected 
were that of IL-10 encoded by Orf virus and Bovine 
papular stomatitis virus, and the A-type inclusion protein 
of Pseudocowpox virus and Orf virus, as well as the 
glycoprotein of Orf virus (Supplementary Table 2). 
Specific signatures of poxviruses detected were sequences 
of thymidine kinase (66R) and ankyrin repeat (147R) 
of the tumorigenic Yaba monkey tumor virus, 3-beta-
hydroxysteroid dehydrogenase of Yaba-like disease 
virus (Supplementary Table 2). Also, the majority of the 
Polyomavirus probes significantly detected in the ovarian 
cancers were that of Merkel cell Polyomaviruses which 
were undetectable in the controls, whereas the majority 
of the Polyomavirus probes detected in the controls were 
that of SV40, traces of which were also detected in the 
cancers (Figure 1F, Supplementary Table 2). Among the 
retroviral probes detected in the majority of cancers were 
Fungal 
signatures
Acremonium
Ajellomyces
Aspergillus
Candida
Cladosporium
Coccidioides
Cryptococcus
Cunninghamella
Issatchenkia
Nosema
Paracoccidioides
Penicillium
Pleistophora
Pneumocystis
Rhizomucor
Rhizopus
Rhodotorula
Trichophyton
Exophiala
Phialophora
Alternaria
Malassezia
Mucor
Trichosporon
Absidia
Cladophialophora
Fusarium
Geotrichum
Parasitic 
signatures
Ancylostoma
Anisakis
Armillifer
Ascaris
Babesia
Balantidium
Bipolaris
Blastocystis
Capillaria
Dicrocoelium
Dipylidium
Echinococcus
Echinostoma
Entamoeba
Enterobius
Hartmannella
Heteroconium
Hymenolepis
Leishmania
Loa
Metagonimus
Necator
Onchocerca
Plasmodium
Sarcocystis
Schistosoma
Strongyloides
Toxascaris
Toxocara
Trichomonas 
Trichuris
Wuchereria
Prosthodendrium
Acanthamoeba
Naegleria
Taenia
Trichinella
Contracaecum
Diphyllobothrium
MC: Matched Control, NC: Non-matched Control.
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Figure 1: Viral signatures detected in ovarian, matched and non-matched controls. (A) Molecular signatures of viral 
groups detected in ovarian cancer, with the total hybridization signal for each viral groups (sum of average hybridization signal for all the 
representative families in the group) represented according to descending order as a bar graph and prevalence of the same as dots. (B) The 
percentage of tumorigenic viral signatures detected in the ovarian cancers are represented in a pie chart. (C) The average hybridization 
signal of the tumorigenic viral signatures detected in the ovarian cancers are represented in the decreasing order as a bar graph, whereas 
their respective prevalence are represented as dots. (D and E) The signatures of viral families detected in matched (D) and non-matched (E) 
controls are represented according to decreasing average hybridization signals as bar graphs, and their respective prevalence as dots. (F) 
Heat map of average hybridization signals for probes of Poxviruses, Retroviruses, Herpesviruses, Polyomaviruses and Papillomaviruses 
detected in ovarian cancers (OC), matched (MC) and non-matched (NC) controls. Heat map of average hybridization signal of both 
conserved and specific probes of Poxviridae are shown. Among the conserved poxviridae probes mentioned, (a) comprises the conserved 
probes detected significantly in the ovarian cancer versus the controls, and (b) comprises the conserved probes detected significantly in 
the controls versus the ovarian cancers screened. In the heat map with Herpesviridae probes, those mentioned (c) are conserved probes. 
All other probes in these heat maps are specific probes. (G) Venn diagram showing the number of viral families common or unique to the 
ovarian cancer and control samples.
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specific probes of Mammary Tumor Virus (MMTV) and 
Foamy Virus (SFV), whereas, the majority of Retroviral 
probes detected in the controls were specific probes 
for the lentivirus subgroup of retroviruses (Figure 1E, 
Supplementary Table 2). Interestingly, the detection 
of Herpesviridae probes identified HHV2 with high 
significance in the non-matched control compared to the 
cancers. However, the cancer samples showed detection 
for conserved and specific probes of HHV6A and 
HHV6B which were undetectable in the controls. Other 
herpesviridae probes of HHV4, HHV5 and HHV8 were 
detected in both cancer and non-matched control samples 
(Figure 1F, Supplementary Table 2).
The data as a whole suggest that specific viral 
signatures are dramatically altered in the cancer tissue. 
Some signatures appear only in the cancer or have 
significantly increased hybridization intensity, while 
others are decreased compared to the surrounding tissue. 
Several points must be kept in mind when considering 
these data: 1) the tumor microenvironment may provide 
advantages for the persistence of some viruses, thus 
promoting their presence in the cancer. Hence, their 
presence need not be related to the cause of the cancer. 
Similarly, the appearance of a virus in the matched 
control and not the cancer may suggest that the tumor 
microenvironment is inhibitory for persistence of the 
virus. 2) The probes may also be detecting relatives or 
variants of known viruses from which the probes were 
derived. For example, specific probes for lentiviruses 
including HIV-1 were positive in the analysis of control 
samples. These are de-identified samples; however we 
doubt that these patients were HIV positive but suspect 
that the probes are likely detecting the presence of a 
related, uncharacterized human lentivirus. 
Identification of bacterial signatures associated 
with ovarian cancer
Similar to that seen with the viruses, the bacterial 
signatures of the tumor tissue were dramatically altered 
from those of matched and non-matched controls. The 
specific bacterial signatures detected in the cancer and the 
matched and non-matched samples are shown in Figure 2A 
according to their decreasing prevalence. Two predominant 
bacterial phyla were detected in the ovarian cancer samples 
screened. They were Proteobacteria (52%), followed by 
Firmicutes (22%) (Figure 2B). We also detected other 
phyla at lower percentages including Bacteroidetes, 
Actinobacteria, Chlamydiae, Fusobacteria, Spirochaetes 
and Tenericutes in the cancer samples. Signatures 
of Proteobacteria and Firmicutes were also detected 
significantly in the matched control samples screened, 
and that of Proteobacteria, Actinobacteria, Bacteroidetes 
and Firmicutes were detected significantly in the non-
matched control samples (Figure 2B). Many more bacterial 
signatures were significantly detected in the cancer samples 
compared to the controls. The signatures associated only 
with the ovarian cancer samples are listed Table 1). The 
different bacterial signatures, unique or common to the 
control and ovarian cancer samples are listed in Table 1 
and represented in Figure 2C. 
While signatures of Pediococcus was detected 
with the highest hybridization signal in the ovarian 
cancer samples screened, followed closely by that 
of Burkholderia, Sphingomonas, Chryseobacterium, 
Enterococcus, Staphylococcus, Treponema and 
Francisella [(log g/log r) > 1], Shewanella signatures 
were detected with the highest prevalence in 
91% of the cancers (Figure 2A). The majority of 
the bacterial signatures detected in the cancers 
had high prevalence, except for signatures of 
Escherichia, Legionella, Streptobacillus, Ureaplasma, 
Clostridium, Geobacillus which were detected in 
less than 50 percent of the cancer samples screened 
(Figure 2A). Interestingly, there are no common 
bacteria between all 3 types of samples (Figure 2C, 
Table 1). However, 5 agents were shared between the 
cancer and non-matched controls, and 3 agents between 
the cancer and matched controls (Figure 2C, Table 1). 52 
unique bacterial agents were detected predominantly in 
only the cancer (Figure 2C, Table 1).
Identification of fungal signatures associated 
with ovarian cancer
Our pathogen screen for fungal signatures again 
suggests a significant perturbation of the microbiome 
in the tumor. The fungal signatures detected in the 
ovarian cancer and controls are shown according to 
their decreasing prevalence in Figure 3A. The 18 fungal 
signatures that were detected only in the ovarian cancer 
samples and interestingly not found associated with 
the controls are listed (Table 1, Figure 3B). 18S rRNA 
signatures of Cladosporium were detected in all the 
ovarian cancer samples with the highest hybridization 
signal (Figure 3A). Signatures of Pneumocystis, 
Acremonium, Cladophialophora, Malassezia and 
Microsporidia Pleistophora were also detected 
significantly in all the ovarian cancer samples screened 
(Figure 3A). Signatures of Rhizomucor, Rhodotorula, 
Alternaria, Geotrichum were found to be associated with 
more than 95% of the ovarian cancer samples screened 
(Figure 3A). It should be noted that the signature of 
Geotrichum was also detected in all the control samples 
(Table 1 and Figure 3A). Therefore the associated fungal 
agents appear to be dominant in the ovarian cancer with 
only Geotrichum common among the cancer and controls. 
This suggests that the fungal signatures may be more 
tightly associated in this particular microenvironment 
than previously predicted.
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Identification of parasitic signatures associated 
with ovarian cancer
The parasitic signatures detected in the ovarian 
cancer and controls are shown (Figure 4A), according 
to their decreasing prevalence. The parasitic signature 
significantly detected in cancer samples was far more 
complex than the matched and, especially, the non-
matched controls, once again suggesting a marked 
perturbation of the tumor microbiome. The parasitic 
signatures detected only in the ovarian cancer samples 
are listed (Figure 4B, Table 1). All of the tumor samples 
showed a high hybridization signal (log g/log r > 2) for the 
28S rRNA signature of Dipylidium. A high hybridization 
signal for the 18S rRNA signatures of Trichuris and 
Leishmania was also found in all of the ovarian cancer 
samples (Figure 4A). The 18S rRNA signatures of Babesia 
were also significantly detected in all the ovarian cancer 
samples, although with a relatively moderate hybridization 
signal (log g/log r > 1, < 2) (Figure 4A). 18S rRNA 
signatures of Trichinella, Ascaris, and Trichomonas 
were detected in >95% of the ovarian cancer samples 
screened, also with a moderate hybridization signal 
intensity (log g/log r > 1, < 2) (Figure 4A). The other 
parasitic signatures detected in the ovarian cancer listed in 
Figure 4A were detected with lower hybridization signal 
intensity (log g/log r < 1), although with high prevalence 
except for signatures of Loa loa, Acanthamoeba, Taenia, 
Dicrocoelium, Wuchereria which were detected in 
less than 45% of the ovarian cancer samples screened. 
Signatures of 4 parasites that were detected in the cancer 
samples were also found in the adjacent matched control 
samples; these include Acanthamoeba, Naegleria, Taenia 
and Trichinella (Figure 4A, Table 1). However, they were 
not detected in the non-matched controls (Figure 4A).
Hierarchical clustering of the ovarian cancer 
samples
Hierarchical clustering analysis compares the 
similarity of the overall microbiome signatures detected 
in each ovarian cancer sample and clusters the samples 
together based on common microbiome similarity 
(Figure 5A–5B). While some samples did not group 
into a cluster (namely un-grouped 1 and 2) (Figure 5B), 
majority of the samples grouped into three distinct clusters, 
namely cluster 1, 2 and 3 (Figure 5A and 5B), with cluster 
3 samples showing significant differences in detection of 
several viral and other microbial signatures compared to 
the samples of cluster 1 and 2. Supplementary Table 3 
shows the significant differences in microbial detection 
between the clusters. Ovarian cancer samples of cluster 1 
Figure 2: Bacterial signatures detected in ovarian, matched and non-matched controls. (A) Bacterial signatures detected in 
ovarian cancers, matched and non-matched controls. The prevalence of those signatures are represented in the decreasing order as dots, and 
their average hybridization signal being represented as a bar graph. (B) Distribution of bacterial phyla detected in ovarian cancer, matched 
and non-matched controls. (C) Venn diagram showing the number of bacteria common or unique to the ovarian cancer and control samples.
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and 2 showed significant differences in the detection of 2 
viral agents (Arenaviridae and Flaviviridae) and bacterial 
agents (Coxiella and Listeria) signatures, and few fungal 
(Acremonium, Cladosporium, Mucor, Pleistophora, 
Pneumocystis and Rhodotorula) and parasitic (Babesia, 
Dipylidium, Leishmania, Toxocara, Trichinella, 
Trichomonas and Trichuris) signatures. These signatures 
are all of higher intensities in cluster 2 than 1. On the other 
hand, ovarian cancer samples of cluster 3 had significantly 
less detection of almost all the viral and several microbial 
signatures mentioned in Supplementary Table 3.
Based on topological analysis, the ovarian cancer 
samples clustered into 3 groups (A, B and C), while some 
could not be grouped together (singletons) (Figure 5C). 
Supplementary Table 4 shows significant differences in 
microbial detection in each groups. Group B had significantly 
higher detection of the following signatures compared to Group 
A: viral signatures of Coronaviridae, Astroviridae, Togaviridae, 
Reoviridae, Papillomaviridae, Poxviridae, Bunyaviridae, 
Picornaviridae, Paramyxoviridae, Bornaviridae, Birnaviridae, 
Rhabdoviridae, Caliciviridae, Arenaviridae and Flaviviridae; 
along with certain bacterial signatures of Porphyromonas, 
Anaplasma, Azorhizobium, Corynebacterium, Arcobacter, 
Lactococcus, Methylobacterium, Shigella, Proteus, Brucella, 
Ureaplasma and Prevotella; fungal signatures of Absidia, 
Trichophyton, Ajellomyces, Geotrichum and Candida;and 
parasitic signatures of Ascaris, Bipolaris, Acanthamoeba, 
Sarcocystis, Balantidium, Echinostoma, Dicrocoelium 
and Wolbachia. Group C differed from group B in having 
significantly higher signatures of mainly viral families of 
Poxviridae, Papillomaviridae, Coronaviridae, Bunyaviridae, 
Retroviridae, Herpesviridae, Reoviridae, Anelloviridae 
and Togaviridae and bacterial signatures of Rickettsia and 
Legionella compared to Group B. Group C differed from 
Group A in having significantly higher detection of the viral 
signatures of Poxviridae, Togaviridae, Papillomaviridae, 
Coronaviridae, Bunyaviridae, Herpesviridae, Anelloviridae, 
Retroviridae, Reoviridae, Parvoviridae, Rhabdoviridae, 
Paramyxoviridae, Arenaviridae, Picornaviridae, Circoviridae, 
Flaviviridae, Adenoviridae, Birnaviridae, Caliciviridae, 
Polyomaviridae, Orthomyxoviridae, Iridoviridae, 
Bornaviridae, Astroviridae; bacterial signatures of Legionella, 
Figure 3: Fungal signatures detected in ovarian, matched and non-matched controls. (A) Fungal signatures detected in 
ovarian cancer, matched and non-matched controls. The prevalence of those signatures are represented in the decreasing order as dots, and 
their average hybridization signal being represented as a bar graph. (B) Venn diagram showing the number of fungi common or unique to 
the ovarian cancer and control samples.
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Porphyromonas, Lactococcus, Prevotella, Bartonella, 
Pseudomonas, Arcobacter, Helicobacter, Bordetella and 
Proteus; fungal signature of Nosema, Ajellomyces, Rhizopus, 
Cunninghamella, Candida, and Trichosporon; and parasitic 
signature of Schistosoma, Echinococcus and Hymenolepis. 
The cancer samples which could not be grouped into a cluster 
(Singletons) showed significant differences in the detection 
of certain viral and microbial signatures than the rest of the 
clustered samples (Supplementary Table 4). The bacterial 
signature of Abiotrophia was detected significantly higher 
in the grouped ovarian cancer samples than the ungrouped 
singletons. However, in the singletons compared to the grouped 
samples (Group A+B+C) there was significantly higher 
detection of most viral signatures (except for Hepadnaviridae 
and Nodaviridae), bacterial signatures of Pseudomonas, 
Lactobacillus, Streptococcus, Abiotrophia, Mycoplasma, 
Rickettsia, Bordetella and Bacillus; fungal signatures of 
Paracoccidioides, Ajellomyces, Malassezia and Penicillium; 
and parasitic signatures of Schistosoma, Entamoeba and 
Naegleria.
Pathochip screen validation and detection of 
viral insertions in human chromosomes of 
ovarian cancer cells
Probes of certain viruses, which were detected 
positive in the PathoChip screen were used as a target 
reagent (Supplementary Table 5) to capture the genomic 
sequences of amplified products of the pooled ovarian 
samples. The selected targets were then subjected to 
next generation sequencing. The sequences, when 
aligned to the PathoChip metagenome, showed that 
they aligned at or near the capture probe locations, thus 
validating the PathoChip screen results (Figure 6 and 
Supplementary Figure 2). The sequence alignments to 
the PathoChip metagenome were visualized using the 
Integrative Genomics Viewer (IGV) program. Capture 
probes of Yaba Monkey Tumor virus, HTLV-2, HHV6a, 
Human adenovirus D, HPV16, HPV18, HPV2 and 
Iridovirus (Frog virus 3) also hybridized to and captured 
the viral sequences from the ovarian cancer samples 
(Supplementary Figure 2). The YMTV sequence identified 
the g52R ORF.
We also determined from our analyses that there were 
certain viral genomic integrations in the host chromosomes, 
by the Virus-Clip method described in the material and 
methods section (Figure 7 and Supplementary Table 6). We 
identified regions of some of the sequences that aligned to 
the PathoChip metagenome to contain soft-clipped segments, 
which could not be aligned to the metagenome (Figure 7A). 
However, these sequence segments did map to the human 
genome indicating specific sites of microbial genomic 
integrations in the human genome. We detected the highest 
number of viral integration sites in human chromosomes for 
Figure 4: Parasitic signatures detected in ovarian, matched and non-matched controls. (A) Parasitic signatures detected in 
ovarian cancer, matched and non-matched controls. The prevalence of those signatures are represented in the decreasing order as dots, and 
their average hybridization signal being represented as a bar graph. (B) Venn diagram showing the number of parasites common or unique 
to the ovarian cancer and control samples.
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Figure 5: Hierarchical clustering of ovarian cancer samples screened. Hierarachial clustering of 99 ovarian cancer samples. 
(A). Hierarchial clustering by R program using Euclidean distance, complete linkage and non-adjusted values. Samples marked (▪) were 
the samples that were screened in pools, rest were screened individually. (B). Clustering of the OSCC samples using NBClust software [CH 
(Calinski and Harabasz) index, Euclidean distance, complete linkage]. (C). Topological analysis using Ayasdi software, using Euclidean 
(L2) metric and L-infinity centrality lenses. The cancer samples that had similar detection for viral and microbial signatures formed the 
nodes, and those nodes are connected by an edge if the corresponding node have detection pattern in common to the first node. Each nodes 
are colored according to the number of samples clustered in each node. 
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HPV16 with over 30 integrations (Figure 7B–7D) with 5 
integrations in the X-chromosome and 3 in chromosome 6 
(Figure 7B, Supplementary Table 6). This was followed by 
HHV6a, HHV7 and HHV3 with less than 10 integrations 
(Figure 7B–7D, Supplementary Table 6). The genes at or 
proximal to which we detected the viral integrations were 
then subjected to Ingenuity Pathway Analysis (IPA) software 
[11], to determine if those genes were associated with the 
development of cancer (Figure 7E). The software calculates 
the significance of such associations.
Figure 6: Targeted MiSeq reads align to capture probe locations. Probe capture sequencing alignment is shown for individual 
capture pools (Capture 1-6 or, C1-6). The whole genome amplified DNA plus cDNA of the ovarian cancer samples were hybridized to a set 
of biotinylated probes, then captured by streptavidin beads, and used for tagmentation, library preparation and deep sequencing with paired 
–end 250-nt reads. The total number of MiSeq reads per capture pool for HPV18 (A) and Yaba Monkey Tumor Virus (B) are mentioned 
at the right end of the read coverage track. For example we obtained 302 reads for C2 capture. The miseq reads from individual capture 
when aligned with the metagenome of PathoChip (Chip probes) was found to cluster mostly at the capture probe regions. The genomic 
location are mentioned in the figure for each organism. Figure A shows the MiSeq read alignement to the HPV18 probes on the PathoChip. 
The probes corresponding to the HPV18 genes are mentioned. It also shows the heat map of hybridization signals of all the HPV18 probes 
in the PathoChip with the ovarian samples. The HPV18 probes marked (*) are the probes that were biotinylated and used for capture of 
the HPV18 sequences from the whole genome amplified DNA plus cDNA of the ovarian cancer samples. Figure B shows the MiSeq read 
alignement to the PathoChip probes for Yaba Monkey Tumor Virus. MiSeq reads aligned to the 1 capture probe used which corresponded 
to g52R gene of the virus.
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Identification of HPV insertions in ovarian 
cancer
Examination of the HPV insertion data shows 
integration of HPV16 genomic sequences around the 
polyA sequence of E5 (co-ordinate 4184–4213 of 
NC_001526.2), which was known to be hotspot for 
integration [12], integrated at intronic and intergenic 
regions of a number of human chromosomes 
(Supplementary Table 6). HPV16 integration was seen 
at the intronic regions of MAST4 (chr5), IFT122 (chr3), 
CYFIP1 (chr15), EEPD1 (chr7), C11orf49 (chr11), SYT1 
(chr12), HERC2P3 (chr15), ZNF71 (chr19), ASCC3 
(chr6), GCSAML (chr1), MTMR8 (chrX), SIL1 (chr5), 
CNTN4 (chr3), KDM4B (chr19), METTL20 (chr12), 
DPP10 (chr2) and SENP6 (chr6). We also detected 
HPV16 genomic integrations at about 29 Kb upstream 
of the SLC7A1 gene (chr13), 15 Kb upstream of the 
SHISA6 (chr17), 56 Kb upstream of the ncRNA gene 
LOC101928137 (chr12), 21Kb upstream of GS1-600G8.3 
(chrX), 33 Kb upstream of CCDC71L (chr7), 12 Kb 
upstream of LONRF3 and 81 Kb downstream of ncRNA 
LINC01285 (chrx), 26 Kb downstream of LOC644172, 
and 53 Kb upstream of LRRC37A4P (chr17).
Regions from the coding sequence of the E1 
gene of HPV18 were found to be integrated at the 
intronic regions of ncRNAs LOC100131564 (chr1) and 
MIR548AZ (chr14), as well as at intergenic regions of the 
mitochondria chromosome. Genomic regions of the L1 
gene of HPV18 were also detected at the intronic region 
of the NRXN3 gene (chr14). Among other HPV insertions, 
we detected the coding sequence of the L1 gene of HPV2 
at the intronic region of the CLVS1 gene in chr8. Of the 
36 genes that could be affected due to HPV genomic 
insertions, 21 were found be significantly associated with 
malignant solid tumors (p value =1.06E-02) as predicted 
by Ingenuity Pathway Analysis software [11] (Figure 7E). 
Of the probable 32 genes that could be affected by HPV 
16 genomic insertion at or near those genes, 18 of them, 
namely ASCC3, C11orf49, CCDC71L, CNTN4, DPP10, 
GCSAML, HERC2P3, IFT122, KDM4B, LONRF3, 
MAST4, MTMR8, SENP6, SHISA6, SIL1, SLC7A1, 
SYT1 and ZNF71 were found to be significantly 
associated with malignant solid tumors (p- value = 
1.22E–02) (Figure 7E). Among the other HPV genomic 
insertions detected that could affect gene expression of 4 
others, 2 genes, MIR548AZ and NRXN3 were affected by 
HPV18 genomic integration at the intronic region and the 
CLVS1 gene which was affected by intronic integration of 
HPV 2 were also found to be significantly associated with 
malignant solid tumor formation (Figure 7E).
Herpes virus insertions within the ovarian 
cancer chromosomes
Among the herpesviridae genomic insertions we 
detected were that of HHV6a, KSHV, Herpesvirus 4, 
Herpesvirus 1, Herpesvirus 2, HHV3 and HHV7 (Figure 
7B–7D, Supplementary Table 6). Of the 36 genes, at 
or proximal, we detected many herpesviral genomic 
integrations. 32 were significantly associated with 
tumorigenesis (p-value = 8.45E-07) as predicted by IPA 
software (Figure 7E). Coding sequence (CDS) of the U47 
gene of HHV6a (NC_001664 at 76981) which encodes 
for the envelope glycoprotein O, involved in virion 
morphogenesis was found to be integrated at various 
regions of the host chromosome (chr), namely at the 
intronic region of SH3RF2 gene (chr 5), ZNF616 gene 
(chr19), SYNDIG1 gene (chr20), CPLX1 (chr4), at the 
exonic region of OR5I1 (chr11), at the downstream of 
DPY19L1 (chr7), and at certain intergenic regions like 
58Kb upstream of LHX1 and 25Kb upstream of IGFBP3 
(chr7) (Supplementary Table 6). Most of these genes 
which may be affected due to HHV6a genomic insertions 
at or near the genes except for LHX1 were found to be 
significantly associated with different cancers (p-value = 
8.54E–04) (Figure 7E).
Many of the capture probes used were from the 
conserved sequences of Herpesviruses (Supplementary 
Table 5), and these conserved probes allowed for detection 
of Herpesvirus 4, Herpesvirus 1, Herpesvirus 2 genomic 
sequences integrated at various somatic chromosomal 
Figure 7: Viral genomic integrations in the host chromosome. (A). Alignment of the MiSeq reads to the reference of HHV6A, 
showed soft-clipped regions that do not align to the corresponding viral reference sequences. These soft-clipped reads shown were then 
extracted from the alignment and mapped (containing sequences of potential pathogen-integrated human loci) to the human genome, 
which reveals the exact human and pathogen integration breakpoints. (B). Karyogram plot of virus insertion sites in human chromosomes. 
All the insertion sites were included. The number of insertion sites in each chromosome is mentioned in the figure before chromosome 
number. G-banding annotation for each chromosome is shown; gneg - Giemsa negative bands; The Giemsa positive bands have further 
been subdivided into gpos25, gpos50, gpos75, and gpos100 with the higher number indicating a darker stain; acen - centromeric regions; 
gvar - variable length heterochromatic regions; stalk - tightly constricted regions on the short arms of the acrocentric chromosomes (C). 
Circos plot highlighting fusion events for the viral insertions into individual human chromosomes. All the reads were taken into account 
and chromosome numbers are mentioned. Viral insertions for individual families are represented in the inner concentric circular tracks. 
The outermost track shows all the insertions taken together highlighting the karyotype of each chromosome. (D). The number of individual 
viral genomic insertions in human somatic chromosomes detected in the study are shown. (E) Association of host genes affected by viral 
genomic integrations to malignant tumor formation, analysed by Ingenuity Pathway Analysis (IPA) program that showed highly significant 
p- value for such association.
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locations (Supplementary Table 6); CDS of ORF71 
of Herpesvirus 4 was detected integrated within the 
intergenic region of chromosome M, genomic sequence 
matching to the CDS of ORF18 of Herpesvirus 1 was 
found integrated at the intronic region of BTBD11 (chr12), 
and genomic sequence of the CDS of UL42 gene which 
encodes the DNA polymerase processivity subunit for 
DNA replication was found to be integrated at the intronic 
region of the NEO1 gene (chr15). Both of these genes 
are found to be associated with endometrioid carcinoma 
(p-value = 2.27E–02) (Figure 7E).
CDS of vIRF-2 (viral interferon regulatory factor 2) 
of HHV8 was found to be integrated 57Kb downstream of 
DRAM2 (chr 1), while tegument protein coding sequence 
was seen to be integrated at the intronic region of the 
PDSS2 tumor suppressor gene (chr6) [13] (Supplementary 
Table 6). Again, both of these genes were associated with 
cancer (Figure 7E).
Interestingly, we detected CDS of ORF6 that 
encodes the helicase-primase subunit for DNA replication 
of the HHV3 sequence integrated at multiple sites of 
different chromosomes (Supplementary Table 6). This 
region could be a hotspot for HHV3 integrations within 
the host chromosomes. We detected insertions at the 
intronic regions of TMEM192 (chr4), ATXN1 (chr6), 
APBA2 (chr15), CTNND2 (chr5), upstream of HELB 
(chr12), at a position that is just upstream of CHRNA5 
and downstream of PSMA4 (chr15), as well as at certain 
intergenic regions in certain chromosomes. We detected 
intergenic insertions which includes regions 13 Kb 
downstream of SMPX and 34Kb upstream of KLHL34 
in X chromosome, 10Kb upstream of ELFN1 and 82Kb 
downstream of TFAMP1 (chr7). Except for TFAMP1, 
all other genes are found to be associated with epithelial 
cancer (p- value = 2.11E–03) (Figure 7E).
Similar to the HHV3 data, we detected a specific 
region of the HHV7 genome to be integrated at multiple 
sites in the chromosomes (Figure 7B–7C, Supplementary 
Table 6). The CDS of the U30 gene of HHV7, encoding the 
tegument protein UL37 that helps in virion morphogenesis 
was found to be integrated at the intronic or intergenic 
region of certain chromosomes. We detected HHV3 
insertions at the intronic regions of ZNF225 (chr19), 
TENM1 (chrX) and HTR2C (chrX), and also at certain 
intergenic regions, some of which are less than 35Kb from 
the affected genes. Therefore, this may have an effect on 
promoting or suppressing the transcription of those genes. 
For example, we detected insertions 17 Kb downstream 
of RASSF6 and 26 Kb downstream of LOC728040 in 
chromosome 4; 32 Kb downstream of GDAP1 (chr8); 
11 Kb downstream of USP15 and 46Kb upstream of 
MON2 (chr12); 35Kb downstream of GABRA2 and 90 
Kb upstream of GABRG1 (chr4). Except for LOC728040, 
the other genes having HHV7 genomic insertions at or in 
their proximity were seen to be significantly associated 
with adenocarcinoma (p- value = 2.33E–04) (Figure 7E).
Insertions detected for retrovirus, hepadnavirus, 
yaba monkey tumor virus and frog virus 3
Among the other viral insertions detected were 
HTLV-2 (Supplementary Table 2), whose genomic region 
encoding gag-pro-pol was detected at the intronic region 
of CCDC88C (chr14). The 3ʹUTR region of HCV was 
detected at the intronic, intergenic as well as downstream 
of certain genes in a number of chromosomes. We 
detected insertion at the intronic region of RBM4 (chr11), 
known to be associated with cancer [14] and ncRNA 
SMG1P5 (chr16), downstream of TINAGL1 (chr1) 
and LOC339807 (chr2) and at an intergenic region that 
is 30Kb upstream of ZNF846 and 11Kb downstream 
of FBXL12 in chromosome 19. Interestingly, we also 
detected Yaba Monkey Tumor Virus (YMTV) genomic 
sequences encoding the G protein-coupled chemokine 
receptor-like protein at the intergenic region of a number 
of genes in chromosome 5 (Supplementary Table 2). 
We also detected Alloherpesviridae genomic sequence 
(Frog virus 3) insertions in host chromosomes. CDS of 
FV3gorf8R gene encoding the largest sub-unit of DNA-
dependent RNA polymerase II of Frog virus 3 was inserted 
at the intronic region of FAT3 gene (chr11), upstream of 
PTGDR gene (chr14), 86Kb downstream of C15orf59-
AS1 and 18Kb upstream of TBC1D21 gene (chr15). FAT3 
gene and PTGDR gene, both are shown to be associated 
significantly (p- value = 8.41E–04) with esophageal 
adenocarcinoma by IPA analysis.
DISCUSSIONS
We previously reported 2 distinct microbial 
signatures specifically associated with triple negative 
breast cancer [6]. In the present study we used the same 
pan-pathogen array technology to detect the microbial 
signatures associated with ovarian cancers [6, 9]. 
Evidences from a number of studies have indicated that 
the mutualistic or pathogenic resident or transient viruses, 
bacteria, fungi and parasites in our body may increase 
our potential cancer risk. In this regard it has been shown 
that differences in the microbiome in an individual 
can correlate with different susceptibility to diseases 
[7, 15, 16]. Apart from inducing cancer, the microbiome 
may also influence the course of the cancer. However, it is 
also possible that the tumor microenvironment provided 
a specialized niche in which a specific microbiome can 
persist. In either case establishing the unique microbiome 
of different cancers may provide biomarkers, as well as 
insights for diagnosis, prognosis, prevention and the 
development of treatments for microbe-associated cancers. 
We selected those signatures in cancer samples 
with adjusted p value < 0.05 (adjusted by the Benjamini–
Hochberg procedure), logFC > 0.5. Under the adjusted 
p-value cutoff, we did not observe much significant ones 
present in either of the controls. To provide information 
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as to what are present in control, we present the top ones 
and used nominal p-value < 0.05 as cutoff for the controls 
without any multiple comparison correction. Including 
these nominally significant signatures present in controls 
would provide us some suggestive evidence of detection, 
though caution should be used for potential false positives 
brought by multiple comparison.
Our data show that the microbiome of ovarian 
tumors is quite different from its surrounding non-
cancerous tissue and very different from ovarian tissue 
that has never been in the proximity of a tumor. A defining 
ovarian tumor microbiome signature does emerge from 
the data. The microbiome we detected is robust and, for 
some organisms, unexpected. However, we are using 
a very sensitive approach [9] which can detect not only 
low levels of specific viruses and microorganisms but also 
related members of a viral or microbial family that have 
yet to be characterized. Thus in cases where, for example, 
an unexpected organism is detected it may be a related 
family member that has yet to be characterized in human 
flora. 
We detected a large number of bacterial signatures 
that were significantly detected in cancer versus the 
non-matched controls, as mentioned above, the tumor 
micro-environment may create a milieu favorable to the 
persistence for many bacteria. Only a few studies have 
suggested an association of bacteria with ovarian cancer. 
One case report showed an association of Brucella [17]; 
another has found that 70% of the ovarian cancer tissues 
contained Chlamydia infection which was not seen in 
healthy controls [8]. Chlamydia is known to contribute 
to cancer by inhibiting apoptosis, inducing DNA damage 
response and increasing susceptibility to other infections 
[8]. Mycoplasma has also been found associated with 
59% of the ovarian cancer tissues tested [18]. We detected 
Brucella, Chlamydia and Mycoplasma in 76%, 60% and 
74%, respectively, of the ovarian cancer samples screened.
Among the bacterial genera detected in the 
ovarian cancer, many have been reported earlier to be 
either associated with other types of cancers [19–31], 
for example: Streptococcus, Staphylococcus, Bacillus, 
Mycoplasma, Chlamydophila in lung cancer [19, 22]; 
Pediococcus in pancreatic cancer [19, 23]; Staphylococcus, 
Mycoplasma and Chyseobacterium in breast cancer 
[19, 24, 25]; Fusobacterium and Prevotella in oral cancer 
[19, 26] ; Salmonella in gall bladder cancer [19, 27]; 
Chlamydia in Pulmonary Mucosa-Associated lymphoid 
tissue lymphoma [19, 28]; Streptococcus, Fusobacterium, 
Escherichia and Mycoplasma in colorectal cancer 
[19, 25, 29–31].; as well as Treponema and Streptococcus 
in oesophageal cancer [21].
Fungal infections in immunocompromised cancer 
patients are important causes for morbidity and mortality, 
and are a major therapeutic challenge. Thus an association 
of yeast and zygomycetous fungal infections with cancer 
may be expected. There have been reports of infection 
with Aspergillus, Candida, Rhizomucor, Cladosporium, 
Acremonium, Alternaria, Cryptococcus, Pneumocystis, 
Coccidiodes, Trichosporon, Malassezia, Rhodotorula 
and Geotrichum in different cancer patients [32–36]: all 
of these have been detected in the ovarian cancers in our 
study, with the highest signal intensity detected with the 
probes for Cladosporium in all the cancer samples. 
Certain parasitic worms can also raise the risk 
of cancer. For example, infection with Schistosoma is 
associated with several cancers [37–39]. In their hosts, 
parasites establish long-term chronic infections and 
significantly downregulate the host immune response [40]. 
We detected molecular signatures of a number of parasites 
in the ovarian samples, some of them quite surprising, 
but may suggest that sub-clinical infections may be more 
prevalent than presently known. The molecular signatures 
for the zoonotic parasite Dipylidium were detected with the 
highest hybridization signal in all the ovarian cancer samples 
screened. Although there have been reports of Dipylidium 
infection in humans [41, 42], there have been no reports of 
an association with cancers. Trichuris was detected with 
high hybridization signal in all the ovarian cancers screened. 
This correlates with our earlier study where Trichuris was 
detected in 96% of triple negative breast cancer samples 
[6]. There have been other reports which demonstrated an 
association of Trichuris with cancer [43, 44]. Epithelial 
dysregulation and hyper proliferation during chronic 
infection of Trichuris [45] has also been reported, which 
potentially could promote tumorigenesis. The association of 
other parasites like Echinococcus, Strongyloides, Trichinella, 
Schistosoma, Leishmania, Ascaris, Trichomonas to cancer 
was not unique to our study, and has been previously reported 
[44, 46–50]. 
Our study shows a significant association of 
molecular signatures of 10 viral families with ovarian 
cancer. Among these were specific signatures for parapox 
and pox viruses including Yaba Monkey tumor virus, 
Yaba-like disease virus, Monkeypox virus and Myxoma 
virus. There have been no reports of parapox and pox virus 
association with ovarian cancer; however, the signatures 
of various monkey pox viruses suggest that we may be 
detecting a heretofore uncharacterized human variant. 
One of the most intriguing aspects of our viral data 
is the finding of widespread integration of viral sequences 
into the genome of the tumor tissue. Several studies have 
demonstrated an association of HPV with ovarian cancers 
[2, 3, 51]. We detected molecular signatures of high risk 
HPV16 and 18 along with other low risk HPVs in the 
ovarian cancer samples screened. Interestingly, molecular 
signatures of only low risk HPVs were found associated 
with the non-cancerous controls potentially implicating 
the high risk viruses with the origin or propagation of the 
cancer. In this regard, integration of HPV genomic regions 
into the human genome has been considered an important 
event in cancer development. We have detected the HPV16 
genomic integration hotspot, which is located around the 
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polyA sequence of the HPV16 gene for E5 [12], to be 
integrated at various intronic regions, as well at intergenic 
regions that are within 56Kb upstream of a number of 
cancer related human genes. It is known that insertions, or 
genomic perturbations, within 100Kb upstream of a gene 
can affect gene expression [52, 53], thus the insertions we 
detect could deregulate gene expression. In this regard, 
Ingenuity Pathway Analysis (IPA) showed that many of 
the genes potentially affected by HPV insertion can be 
associated with cancer. 
Integration of HPV also often occurs within the E1 
or E2 regions. These regions become transcriptionally 
inactivate after integration due to disruption of the open 
reading frames [54], this is believed to be a prerequisite 
for oncogenesis. In our study, we have detected the coding 
sequences of the E1 gene of HPV18 to be integrated at 
the intronic regions of non-coding RNA genes in the host 
chromosomes. This ncRNA disruption may potentially 
play a role in the development or progression of 
ovarian cancer [55]. Other than HPV16 and 18 genomic 
integrations, we also detected integration of other low 
risk HPVs, which were again integrated at or near genes 
significantly associated with cancer. 
Research on viral associations with ovarian cancer, 
other than HPVs, is very limited. Several studies have 
shown an association of Polyomaviruses [56] with 
ovarian cancer. Additionally herpesviruses [8, 57], 
and Retroviruses (Mouse mammary tumor virus-like 
DNA) [58, 59] have been detected in 50% and 16%, 
respectively, of ovarian cancers. In the present study, 
we not only detected specific molecular signatures of 
herpesviruses HHV4, HHV8, HHV5, HHV6a and HHV6b 
in ovarian cancer samples, but also detected the HHV6a 
hypervariable U47 region integrated at exonic, intronic 
and intergenic regions, as well as upstream regions of 
certain human genes, and at sub-telomeric regions of 
chromosomes 4 (Supplemental Table 6). There have 
been reports of HHV-6A and HHV-6B viral genome 
integration, mostly in the telomeric/sub-telomeric region 
of several host chromosomes [60, 61]. Since several 
diseases, including cancer, are associated with telomere 
dysfunction, genomic integration of HHV-6a at the 
telomeric region could be a contributing factor to ovarian 
cancer. 
HHV6a integration was also detected at a number 
of significant genomic sites that may relate to the genesis 
of ovarian cancer: 1) HHV6a sequences were found 
integrated 25Kb upstream of the IGFBP3 gene that 
encodes an IGF-binding protein 3 (IGFBP). Insulin-like 
growth factors (IGFs) are mitogens that play an important 
role in regulating cell proliferation and anti-apoptosis and 
thus promotes cancer [62]. Recent studies suggest that 
increased levels of IGF-I are associated with increased risk 
for several common cancers including breast [63], prostate 
[64], lung [65], and colorectum [66] cancers. IGF-binding 
proteins (IGFBPs) can influence the actions of IGFs [62]. 
IGF-binding protein 3 (IGFBP3), is a major IGF-I-binding 
protein that suppresses the mitogenic action of IGF-I 
[62]. Thus genomic perturbation upstream of IGFBP3 
by HHV6A could lead to increased mitogenic action of 
IGF-1. 2) HHV6a sequences were found integrated in 
the intronic region of SH3RF2, an oncogene that is over-
expressed in human cancers and regulates p21-activated 
kinase 4 (PAK4) protein stability. The viral genomic 
integration at the intronic region of the gene may enhance 
the oncogene expression [67]. The integrations which 
results in human-viral fusion transcript may also lead to 
increased expression of a gene, as has been reported for 
HBV integration in hepatocarcinoma [68].
Other herpesvirus integrations sites of interest 
include the insertion of the coding sequences of the HHV1 
UL42 gene within the intronic region of the NEO1 gene 
which expresses neogenin. Low expression of neogenin 
has been found in a variety of human cancers, such as 
pancreatic [69], colon cancer [70], esophageal squamous 
cell carcinoma [71], gliomas [72] and breast cancer [73]. 
Altered expression of neogenin leading to loss of pro-
apoptotic activity can contribute tumorigenesis [74]. 
Additionally the coding sequences of the KSHV vIRF-
2 gene were found integrated 57Kb downstream of the 
Damage-regulated autophagy regulator 2 (DRAM2). 
This may affect its role as an effector molecule for p53-
mediated apoptosis. It is already known that DRAM2 is 
down-regulated in ovarian tumors and reduced expression 
of DRAM2 may contribute to anti-apoptosis in tumor cells 
[75]. The coding sequences of HHV3 ORF6, the helicase-
primase subunit for DNA replication [76], was detected at 
9 separate sites in different chromosomes (Supplementary 
Table 6), thus it could be an HHV3 hotspot for integration. 
Similarly, we detected coding sequences of the HHV7 
U30 gene, the UL37 tegument protein [77], integrated 
at multiple sites in different chromosomes, which 
again could be an integration hotspot for HHV7. The 
supplemental data contains all of the integration site data 
for all viruses tested.
In conclusion, our data suggests that due to the 
nature of ovarian tumor and its micro-environment, 
significant perturbations have occurred in the ovarian 
microbiome, resulting in a specific ovarian tumor 
microbiome signature. These changes may relate to 
the genesis or propagation of the cancer, alternatively 
the tumor micro-environment may provide a favorable 
milieu for these micro-organisms to persist. We feel 
that these data provide a valuable biomarker for ovarian 
cancer which, when correlated with patient treatment 
and outcome data, may be diagnostic, prognostic and 
guide treatment approaches. Further, understanding the 
contributions of these signatures may guide additional 
research activities into the molecular pathogenesis of 
ovarian cancer.
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MATERIALS AND METHODS
Study samples
The study was approved by the institutional review 
board at the University of Pennsylvania (Protocol number 
819358). The computerized records at the a) Tumor Tissue 
and Biospecimen Bank and b) the clinical archives of 
the Department of Pathology and Laboratory Medicine 
were searched and a total of 99 primary and recurrent 
or metastatic tumors of ovarian origin were identified 
(Supplementary Table 1). Both the metastatic or recurrent 
tumor were still of ovarian origin. Histology of the cases 
evaluated included malignant surface epithelial tumors 
(serous, endometrioid, mucinous, clear cell, transitional 
cell, mixed types and carcinosarcoma) and 1 case of small 
cell carcinoma, hypercalcemic type. The matched control 
tissues were non-tumor ovarian tissue from ipsilateral 
or contralateral ovary from 20 ovarian cancer patients 
(Supplementary Table 1). The non-matched control benign 
tissues were from prophylactic oophorectomy surgery in 
women with BRCA mutations. 
The original H&E slides were reviewed and one 
representative formalin-fixed, paraffin-embedded tissue 
block was chosen per case and cut. Tumors needing 
macro-dissection were received in the form of 10µm 
sections on glass slides with marked guiding H&E slides, 
while tumors that did not require macro-dissection were 
received as 10 µm paraffin rolls. 
PathoChip design, sample preparation and 
microarray processing
The PathoChip Array design has been previously 
described in detail [6, 9]. Briefly, the probes were 
generated in silico from a metagenome of 58 chromosomes 
comprising the genomes of all known viruses as well as 
known human bacterial, parasitic and fungal pathogens 
[9]. PathoChip comprises 60,000 probe sets manufactured 
as SurePrint glass slide microarrays (Agilent Technologies 
Inc.), containing 8 replicate arrays per slide. Each probe 
is a 60-nt DNA oligomer that targets multiple genomic 
regions of the viruses and higher pathogens [9]. 
PathoChip screening was done using both DNA and 
RNA extracted from formalin-fixed paraffin-embedded 
(FFPE) tumor tissues as described previously [6, 9]. 99 de-
identified FFPE samples of invasive epithelial malignant 
tumors of ovarian origin were received as 10 µm sections 
on non-charged glass slides from the Abramson Cancer 
Center Tumor Tissue and Biosample Core. Additionally, 
20 matched and 20 non-matched control samples were 
provided as paraffin rolls. Matched controls were obtained 
from the adjacent non-cancerous ovarian tissue of the 
same patient from which the cancer tissues are obtained, 
non-matched controls were the ovarian tissues obtained 
from non-cancerous individuals. DNA and RNA were 
extracted in parallel from 5 rolls or mounted sections of 
each FFPE sample. The quality of the extracted nucleic 
acids was determined by agarose gel electrophoresis and 
the A260/280 ratio. The extracted RNA and DNA samples 
were subjected to whole transcriptome amplification 
(WTA) as previously described [6, 9]. RNA and DNA from 
40 cancer samples were subjected to WTA individually, 
and the rest were pooled in groups of 4–5 samples 
together, so that 99 samples were screened in 54 arrays. 
20 of each type of controls were also pooled in groups of 
5 for the WTA step, so that we have 4 arrays for each of 
the control types. The WTA products were analyzed by 
agarose gel electrophoresis. Human reference RNA and 
DNA were also extracted from the human B cell line, 
BJAB and were used for WTA as previously described 
[6, 9]. The WTA products were purified, (PCR purification 
kit, Qiagen, Germantown, MD, USA); the WTA products 
from the ovarian cancers were labeled with Cy3 and 
those from the human reference DNA were labeled 
with Cy5 (SureTag labeling kit, Agilent Technologies, 
Santa Clara, CA). The labeled DNAs were purified and 
hybridized to the PathoChip as described previously 
[6, 9]. Post-hybridization, the slides were washed, scanned 
and visualized using an Agilent SureScan G4900DA array 
scanner [6, 9].
Microarray data extraction and statistical 
analysis
The microarray data extraction and analyses have 
been described previously [6, 9]. The raw data from the 
microarray images were extracted using Agilent Feature 
Extraction software [6, 9]; Apart from the previously 
described method we also used the R program for 
normalization and data analyses [78]. We calculated 
scale factor using the signals of green and red channels 
for human probes. Scale factors are the sum of green/
sum of red signal ratios of human probes. Then we 
used scale factors to obtain normalized signals for all 
other probes. For all probes except human probes, 
normalized signal is log2 transformed of green signals 
/ scale factors modified red signals (log2 g – log2 scale 
factor * r). On the normalized signals, t-test is applied 
to select probes significantly present in cancer samples 
by comparing cancer samples versus controls (un-
matched and matched controls) and to select probes 
significantly present in un-matched or matched controls 
versus the cancer samples. The significance cutoff 
was log2 fold change > 0.5 and the adjusted p-value 
< 0.05. The adjusted p-values were obtained for multiple 
corrections by using the Benjamini–Hochberg procedure 
[79]. We detected no significant ones in control under this 
adjusted p-value cutoff. So we present the top ones in 
control with nominal p-value < 0.05 without any multiple 
comparison correction, in order to have a comparison with 
the significant ones present in cancer samples. Prevalence 
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was calculated based on the detection of the signatures in 
the cancer and the control samples as percentage.
The cancer samples were also subjected to 
hierarchical clustering, based on the detection of microbial 
signatures in the samples, using the R program (Euclidean 
distance, complete linkage, non-adjusted values) [78, 80], 
and the clusters were validated by CH index (Calinski and 
Harabasz index) which is implemented in R package as 
NbClust [81]. CH index is a cluster index that maximize 
inter-cluster distances and minimize intra-cluster 
distances. We calculated the possible cluster solution 
that would maximize the index values to achieve the best 
clustering of the data. The significant differences between 
the clusters observed by these methods were determined 
using t-test. Additional topological-based data analyses 
were conducted using the Ayasdi software (Ayasdi, Inc.), 
(using Euclidean (L2) metric, and L-infinity centrality 
lens), where statistical significance between different 
groups was determined using the two-sided t-test.
Probe capture and next generation sequencing
Probe Capture method has been previously described 
[6, 9]. Briefly, selected PathoChip probes that identified 
microbial signatures in the ovarian cancer samples were 
made as biotinylated derivatives and used to capture the 
microbial target nucleic acid from pooled WTA products 
from the ovarian cancer samples. Hybridization was 
followed by capturing the targeted sequences using 
Streptavidin coated magnetic beads as previously described 
[6, 9]. The libraries of the targets were generated for NGS 
using Nextera XT sample preparation kit (Illumina, San 
Diego, CA, USA) [6, 9]. 6 libraries were generated, ov1-6. 
The selected probes used for the target capture are listed 
in (Supplementary Table 5). The libraries were submitted 
to the Washington University Genome Technology Access 
Center (St. Louis, MO) for quality control measurements, 
library pooling, and sequencing using an Illumina MiSeq 
instrument with paired-end 250-nt reads. Adapters and low-
quality fragments of raw reads were first removed using 
the Trim Galore software (http://www.bioinformatics.
babraham.ac.uk/projects/trim_galore/). The processed 
reads were then aligned to the PathoChip metagenome and 
the human genome using Genomic Short-read Nucleotide 
Alignment Program (GSNAP) [82] with default parameters. 
Post alignment feature Counts [83] was employed to count 
the number of reads aligned to each of the capture probe 
regions, and visualized in IGV [84] (Figure 6).
Virus fusion identification
Prior to fusion detection, raw reads were trimmed 
in order to remove adapters and low-quality fragments 
by Trim Galore software (http://www.bioinformatics.
babraham.ac.uk/projects/trim_galore/). We then used 
Virus-Clip [85] to identify the virus fusion sites in the 
human genome. Specifically, the virus genome was used 
as the primary read alignment target, and first aligned the 
reads to the PathoChip metagenome. Some of the mapped 
reads contained soft-clipped segments, which were then 
extracted from the alignment (potentially containing 
sequences of pathogen-integrated human loci) and mapped 
to the human genome. Using this mapping information, we 
could pinpoint the exact human and pathogen integration 
breakpoints at single-base resolution. All the integration 
sites were then automatically annotated with the affected 
human genes and their corresponding gene co-ordinates 
from the human genome maps. 
The affected host genes at or near the viral genomic 
integration sites were analyzed by Ingenuity Pathway 
software to determine if there were any significant 
association with cancer [11]. 
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